TRIB2 and esophageal squamous cell carcinoma: The pharmacologic inhibition of HDAC2 could serve as a viable therapeutic approach for ESCC patients exhibiting hyperactivation of the METTL14–miR‐99a‐5p–TRIB2 axis.